A phase 2a study to investigate the effect of a single dose of migalastat HCl, a pharmacological chaperone, on agalsidase activity in subjects with Fabry disease

David Warnock, Daniel Bichet, Myrl Holida, Ozlem Goker-Alpan, Kathy Nicholls, Mark Thomas, Francois Eyskens, Suma Shankar, Majed Dasouki, Franklin Johnson, Pol Boudes
  • Molecular Genetics and Metabolism, February 2013, Elsevier
  • DOI: 10.1016/j.ymgme.2012.11.262

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication


The following have contributed to this page: Mr Myrl D. Holida and M.D. DANIEL G BICHET